Obesity News

Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

Quality testing of three counterfeit semaglutide products found low purity and more measured semaglutide than what was on the label, according to a research letter published in JAMA Network Open.

The number of monthly prescription fills for semaglutide increased by 442% from 2021 to 2023, according to a research letter published in JAMA Health Forum.

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

Tirzepatide significantly reduced HF outcomes and symptoms for patients with HF and preserved ejection fraction and obesity, according to the top-line results of the phase 3 SUMMIT clinical trial.

Individuals with unhealthy lifestyles may derive the most benefit from aspirin for colorectal cancer prevention, according to results of a prospective cohort study.

Incidence rates for 17 different cancer types increased for successively younger generations in the United States during the past century.

The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.

Older adult cancer survivors who were overweight or obese at the time of first primary cancer diagnosis had a higher risk for developing second cancers, according to findings presented at ASCO Annual Meeting.